Skip to main content
Clinical Trials/NCT04950426
NCT04950426
Completed
Phase 2

Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome

Centre Hospitalier Henri Laborit2 sites in 1 country17 target enrollmentAugust 13, 2021

Overview

Phase
Phase 2
Intervention
Propranolol
Conditions
Fibromyalgia Syndrome
Sponsor
Centre Hospitalier Henri Laborit
Enrollment
17
Locations
2
Primary Endpoint
Significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation therapy.
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

The aim of the study is to demonstrate a significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation blockade.

Patients receive a treatment with propranolol associated with reconsolidation blockade of traumatic story once a week during 6 weeks, with evaluation at inclusion and at 3 months.

Registry
clinicaltrials.gov
Start Date
August 13, 2021
End Date
January 13, 2025
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult over 18 years old
  • Diagnosis of fibromyalgia syndrome according to ACR 2016 criteria
  • PCL-5 \> 44 suggesting the presence of a comorbid post-traumatic stress disorder
  • Meet the DSM-5 criteria for post-traumatic stress disorder secondary to exposure to a traumatic event according to DSM-5 criteria, both unique or repeated and regardless of the date or location of the traumatic event.
  • Pain relief treatment and/or psychotropic treatment stabilized for a period greater than or equal to two months.
  • Signature of a consent form
  • Patient able to understand and read french

Exclusion Criteria

  • Psychotic disorders
  • Unstable bipolar disorder
  • Patients with a systolic blood pressure \< 100 mmHg or heart rate \< 55 as established during the initial visit
  • Significant anormal ECG
  • Medical contraindication to taking propranolol
  • Adverse reactions or previous intolerances to a beta blocker
  • Current intake of another beta blocker which can not be stopped during the protocol, regardeless the galenic.
  • Current intake of a drug with potential contraindication with the propranolol, according to the summary of product characteristics of the propranolol.
  • Patient under legal protection, under guardianship or under curatorship
  • Patient having suffered a head trauma for less than a year or with clinical symptoms and neurological sequelae

Arms & Interventions

Treatment with reconsolidation therapy

Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet

Intervention: Propranolol

Outcomes

Primary Outcomes

Significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation therapy.

Time Frame: 3 months

Modification in quality of life in patients with fibromyalgia syndrome measured by the Fibromyalgia Impact Measurement Questionnaire (FIQ). FIQ minimal value:0 (minimum impact) FIQ maximal value: 100 (maximal impact)

Study Sites (2)

Loading locations...

Similar Trials